Solving Pharma’s Data Silo Problem: Why a Linkable Data Infrastructure is Good for Biopharma and Good for Patients

Each year, pharmaceutical companies spend billions on the generation and procurement of data. But despite investing heavily in data, pharma companies are limited by the basic problem of not being able to connect the data they’ve amassed– and thus unlock insights from it.

This white paper explores how leading life sciences organizations are solving the data silo problem by implementing a linkable data infrastructure that protects patient privacy while unlocking the full value of their datasets.

Whether you work in R&D, medical affairs, commercial strategy, or market access, this is essential reading on the future of data-driven pharma.

4 Key Things You’ll Learn in this White Paper

1. What a linkable data infrastructure is and how it connects de-identified patient records across datasets while remaining HIPAA-compliant.
2. The critical role of tokenization, and how using a common token across datasets eliminates silos and enhances longitudinal insights.
3. The steps to build a linkable data infrastructure—and how you can get there using technology already standard in the industry.
4. How leading pharma companies are already leveraging their own linkable data infrastructures to:
   • Integrate real-world data into clinical development
   • Understand therapy adherence and patient outcomes
   • Strengthen health economics and outcomes research (HEOR)
   • Improve commercial targeting and marketing ROI

‍